Acute, Post-operative Pain Clinical Trial
Official title:
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427 IV Infusion in Healthy Subjects
| Verified date | July 2023 |
| Source | SiteOne Therapeutics, Inc. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This randomized, double-blind, placebo controlled, study will be conducted to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. Subjects will be randomized to receive a single dose of ST-2427 or placebo in a Single Ascending Dose (SAD) design. A total of 30 subjects will be enrolled. Subjects will be randomized in a 4:2 ratio of ST-2427 to placebo. Study drug will be blinded to all subjects and investigators.
| Status | Terminated |
| Enrollment | 24 |
| Est. completion date | August 18, 2021 |
| Est. primary completion date | August 18, 2021 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 55 Years |
| Eligibility | Inclusion Criteria: - Only subjects who meet the following criteria will be eligible for inclusion: 1. Healthy adult males and/or females (of non-childbearing potential), 18 to 55 years of age (inclusive) at the time of screening; 2. Body mass index (BMI) within 18.0 to 35.0 kg/m2, inclusive (minimum weight of at least 50.0 kg at Screening); 3. Medically healthy without clinically significant abnormalities at the screening visit, including physical examination and vital signs within the following ranges: heart rate 50 to 100 bpm, systolic blood pressure 100 to 149 mmHg; diastolic 70 to 94 mmHg; 4. The mean QTcF interval duration =450 msec for males and =470 msec for females measured from the triplicate ECGs taken at least 1 minute apart with QT wave corrected for heart rate (HR) using Fredericia's method 5. Hemoglobin/hematocrit, white blood cell (WBC) count, and platelet count equal to or greater than the lower limit of normal range of the reference laboratory (may be confirmed upon repeat testing without Sponsor approval); 6. Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) equal to or less than the upper limit of normal for the reference laboratory (may be confirmed upon repeat testing); results of all other clinical chemistry and urine analytes without any clinically significant abnormality; 7. Non-smokers (including tobacco, e-cigarettes or marijuana), and no use of any tobacco product for at least 1 month prior to admission in the study; 8. Willing and able to provide written informed consent; 9. Willing and able to comply with all study assessments and adhere to the protocol schedule; 10. Have suitable venous access for blood sampling, as determined by an Investigator at screening; 11. If female, be of non-childbearing potential (e.g. post-menopausal as demonstrated by follicle stimulating hormone (>40 mIU/mL), or surgically sterilized by tubal ligation or hysterectomy). Site personnel's review of the subject's medical records, medical examination, or medical history interview is acceptable evidence of female sterilization, verbal confirmation is adequate; 12. If male, willing not to donate sperm from the time of first study drug administration until 90 days after the final administration of study drug. If male and not intending to engage in sexual intercourse over the duration of the study, willing to agree to abstinence at screening. If male and engaging in sexual intercourse, willing to use a double barrier method of contraception (condom and spermicide). The latter criterion applies to all males (and/or female partners) including males who are surgically sterile and must be followed from the time of first study drug administration until 90 days after the final administration of study drug. Exclusion Criteria: - Subjects will be excluded from the study if they meet any of the following criteria: 1. History or presence of significant cardiovascular (including arrhythmia and ventricular tachyphylaxis), pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or surgery within the past 3 months determined by an Investigator to be clinically relevant; 2. Creatinine, blood urea nitrogen (BUN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) equal to 1.5 x upper limit of normal for the reference laboratory (may be confirmed upon repeat testing); 3. History of orthostatic reactions 4. Orthostatic reaction at screening defined as drop in systolic blood pressure by =20 mmHg or drop in systolic blood pressure to <90 mmHg on standing for 3 minutes from the supine position. 5. History of seizure disorders, except for non-complex febrile seizures in childhood with absence of non-febrile seizures in parents and siblings.; 6. Positive urine drug/alcohol testing at Screening or Day -2; 7. Positive test results for HIV-1/HIV-2 Antibodies, Hepatitis B surface Antigen (HBsAg) or Hepatitis C Antibody (HCVAb); 8. Positive test results for COVID-19 (PCR or Antibodies) 9. History of substance abuse or alcohol abuse (defined as greater than 2 standard drinks per day) within the previous 2 years; 10. Use of any prescription medication or any over-the-counter medication, including herbal products and vitamins within 14 days or 5 half-lives (whichever is longer) prior to randomization; 11. Documented hypersensitivity reaction or anaphylaxis to any medication; 12. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to screening, or receipt of a blood transfusion within 1 year of screening; 13. Dosed in another investigational clinical trial within 30 days prior to Screening; 14. Any condition or prior therapy, e.g. seizures, or head trauma, that may lead to CNS effects during the study; 15. Documented or self-reported history of orthostatic hypotension or symptoms of hypotension such as dizziness, syncope or blurred vision upon standing; 16. Any condition which is associated with increased brain permeability, e.g. cerebral ischemia, brain trauma, multiple sclerosis, brain tumors, brain infection. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Altasciences | Overland Park | Kansas |
| Lead Sponsor | Collaborator |
|---|---|
| SiteOne Therapeutics, Inc. | National Institute on Drug Abuse (NIDA) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of Participants With Treatment-emergent Adverse Events | For purposes of monitoring safety, treatment-emergent adverse events (AEs) will be graded using the Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers (FDA 2007) which is appropriate for healthy subjects. | Day 1 through Day 8 | |
| Primary | Number of Participants With Adverse Events Assessed by Blood Pressure | Blood pressure, including orthostatic blood pressure (BP; diastolic blood pressure [DBP], systolic blood pressure [SBP]), will be used to analyze for change from baseline. Adverse events assessed by blood pressure include hypertension and hypotension (MedDRA Preferred Term). | Day 1 through Day 8 | |
| Primary | Number of Participants With Adverse Events Assessed by ECG | Cardiodynamic evaluation will be performed to evaluate the treatment effects on heart rate-corrected QT interval using the Fridericia (QTcF) corrections. | Day 1 through Day 8 | |
| Primary | Number of Participants With Treatment-emergent Events Assessed by Clinical Laboratory Assessments | Descriptive statistics will be used to evaluate the treatment effects on clinical laboratory assessments including clinical chemistry, hematology, and urinalysis. | Day 1 through Day 8 | |
| Primary | Number of Participants With Adverse Events Assessed by Body Weight | Body weight (kg) will be assessed for changes relative to baseline. | Day 1 through Day 8 | |
| Secondary | Pharmacokinetics of ST-2427 Concentration in Whole Blood: Cmax | PK modeling will be performed using compartmental methods. The maximum concentration of ST-2427 in whole blood after the ST-2427 infusion in the SAD. | 0-48 hours | |
| Secondary | Pharmacokinetics of ST-2427 Concentration in Whole Blood: Area Under the Curve | PK modeling will be performed using compartmental methods. The AUC (area under the curve) of ST-2427 in whole blood after the ST-2427 infusion in the SAD. | 0-9 hours | |
| Secondary | Pharmacokinetics of ST-2427 Concentration in Whole Blood: Area Under the Curve | PK modeling will be performed using compartmental methods. The AUC (area under the curve) of ST-2427 in whole blood after the ST-2427 infusion in the SAD. | 0-25 hours |